Cytokinetics, Incorporated (NASDAQ:CYTK) Director John T. Henderson Sells 3,190 Shares

Cytokinetics, Incorporated (NASDAQ:CYTK - Get Free Report) Director John T. Henderson sold 3,190 shares of the firm's stock in a transaction dated Tuesday, April 15th. The stock was sold at an average price of $38.66, for a total transaction of $123,325.40. Following the completion of the transaction, the director now directly owns 66,348 shares in the company, valued at $2,565,013.68. This represents a 4.59 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink.

Cytokinetics Trading Down 3.9 %

Shares of Cytokinetics stock traded down $1.55 during trading hours on Monday, reaching $37.93. 1,879,060 shares of the company's stock were exchanged, compared to its average volume of 1,603,536. The company has a fifty day moving average of $42.55 and a 200-day moving average of $47.53. The company has a current ratio of 9.28, a quick ratio of 9.28 and a debt-to-equity ratio of 5.93. Cytokinetics, Incorporated has a 52-week low of $32.74 and a 52-week high of $68.76. The firm has a market capitalization of $4.52 billion, a price-to-earnings ratio of -7.05 and a beta of 0.94.

Cytokinetics (NASDAQ:CYTK - Get Free Report) last announced its quarterly earnings results on Thursday, February 27th. The biopharmaceutical company reported ($1.26) earnings per share for the quarter, beating analysts' consensus estimates of ($1.29) by $0.03. The company had revenue of $16.93 million during the quarter, compared to analyst estimates of $14.26 million. Sell-side analysts forecast that Cytokinetics, Incorporated will post -5.24 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

CYTK has been the topic of a number of recent research reports. HC Wainwright reaffirmed a "buy" rating and set a $120.00 price objective on shares of Cytokinetics in a research report on Monday. Citigroup initiated coverage on Cytokinetics in a report on Friday, February 7th. They set a "buy" rating and a $86.00 target price for the company. JMP Securities reaffirmed a "market outperform" rating and issued a $78.00 price target on shares of Cytokinetics in a report on Thursday, April 10th. Needham & Company LLC reaffirmed a "buy" rating and set a $72.00 price objective on shares of Cytokinetics in a research note on Tuesday, April 8th. Finally, Evercore ISI upgraded shares of Cytokinetics to a "strong-buy" rating in a research report on Friday, February 7th. Two investment analysts have rated the stock with a hold rating, fifteen have issued a buy rating and one has issued a strong buy rating to the company's stock. According to MarketBeat, the company has an average rating of "Moderate Buy" and a consensus target price of $81.63.

Hedge Funds Weigh In On Cytokinetics

A number of hedge funds have recently made changes to their positions in CYTK. Jones Financial Companies Lllp grew its position in Cytokinetics by 189.8% in the fourth quarter. Jones Financial Companies Lllp now owns 571 shares of the biopharmaceutical company's stock valued at $27,000 after acquiring an additional 374 shares in the last quarter. Centricity Wealth Management LLC acquired a new stake in Cytokinetics during the fourth quarter worth about $29,000. Fifth Third Bancorp lifted its holdings in shares of Cytokinetics by 42.2% in the 1st quarter. Fifth Third Bancorp now owns 981 shares of the biopharmaceutical company's stock worth $39,000 after purchasing an additional 291 shares during the last quarter. Parallel Advisors LLC boosted its holdings in shares of Cytokinetics by 500.5% during the first quarter. Parallel Advisors LLC now owns 1,099 shares of the biopharmaceutical company's stock valued at $44,000 after acquiring an additional 916 shares during the period. Finally, GAMMA Investing LLC boosted its stake in Cytokinetics by 281.0% during the 1st quarter. GAMMA Investing LLC now owns 1,120 shares of the biopharmaceutical company's stock valued at $45,000 after purchasing an additional 826 shares during the period.

About Cytokinetics

Cytokinetics, Incorporated, a late-stage biopharmaceutical company, focuses on discovering, developing, and commercializing muscle activators and inhibitors as potential treatments for debilitating diseases. The company develops small molecule drug candidates primarily engineered to impact muscle function and contractility.